[A Case Report of Stage Ⅳb Thoracic Esophageal Cancer Responding to Multidisciplinary Treatment]. 2022

Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
Dept. of Digestive Surgery, Sakai City Medical Center.

A 68-year-old man was referred to our hospital because of back pain during swallowing. Upper gastrointestinal endoscopy revealed a lower esophageal type 3 tumor. The patient was diagnosed with esophageal squamous cell carcinoma by the biopsy specimen. CT scan showed thoracic lower esophagus wall thickening, left paracardiac lymph node swelling, and a low-density area in the liver. Therefore, the patient was diagnosed with Stage Ⅳb esophageal cancer. After introducing cisplatin plus 5-FU combination therapy, the liver metastasis disappeared. After 9 chemotherapy courses, the patient received radical chemoradiotherapy. After completing chemoradiotherapy, the patient was followed up without any treatment. After 3 years since the treatment initiation, the patient is surviving without any relapse.

UI MeSH Term Description Entries
D008297 Male Males
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077277 Esophageal Squamous Cell Carcinoma A carcinoma that originates usually from cells on the surface of the middle and lower third of the ESOPHAGUS. Tumor cells exhibit typical squamous morphology and form large polypoid lesions. Mutations in RNF6, LZTS1, TGFBR2, DEC1, and WWOX1 genes are associated with this cancer. Oesophageal Squamous Cell Carcinoma
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
December 2022, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
September 1997, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
January 2024, SAGE open medical case reports,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
April 2014, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
December 2019, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
December 2020, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
June 1988, Hinyokika kiyo. Acta urologica Japonica,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
March 2022, Gland surgery,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
July 1993, Gan to kagaku ryoho. Cancer & chemotherapy,
Hana Oiki, and Ryohei Kawabata, and Yusuke Izutani, and Akihiro Kitagawa, and Yuki Ushimaru, and Nobuyoshi Ohhara, and Yuichiro Miyake, and Sakae Maeda, and Ken Nakata, and Kazuhiro Nishikawa, and Atsushi Miyamoto
July 1985, Gan no rinsho. Japan journal of cancer clinics,
Copied contents to your clipboard!